Search Results 1-19 of 19

  • Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein

    Shibata Norihito , Ohoka Nobumichi , Hattori Takayuki , Naito Mikihiko

    … <p>Chromosomal translocation occurs in some cancer cells, resulting in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). … Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although emergence of drug resistance hampers the therapy during long-term treatment. …

    Chemical and Pharmaceutical Bulletin 67(3), 165-172, 2019

    J-STAGE  Ichushi Web 

  • A secondary RET mutation in the activation loop conferring resistance to vandetanib

    Nakaoku Takashi , Kohno Takashi , Araki Mitsugu , Niho Seiji , Chauhan Rakhee , Knowles Phillip P. , Tsuchihara Katsuya , Matsumoto Shingo , Shimada Yoko , Mimaki Sachiyo , Ishii Genichiro , Ichikawa Hitoshi , Nagatoishi Satoru , Tsumoto Kouhei , Okuno Yasushi , Yoh Kiyotaka , McDonald Neil Q. , Goto Koichi

    RET融合遺伝子上に生じるアロステリック効果を持つ二次変異 --分子標的治療薬に対するがんの新しい薬剤耐性メカニズムを発見--. 京都大学プレスリリース. 2018-02-27.

    Nature Communications (9), 2018-02-12

    IR 

  • Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors

    Alam Muntasir , Kuwata Takeo , Shimura Kazuya , Yokoyama Masaru , Ramirez Valdez Kristel Paola , Tanaka Kazuki , Maruta Yasuhiro , Oishi Shinya , Fujii Nobutaka , Sato Hironori , Matsuoka Masao , Matsushita Shuzo

    … Background: HIV-1 typically develops resistance to any single antiretroviral agent. … Combined anti-retroviral therapy to reduce drug-resistance development is necessary to control HIV-1 infection. … Here, to assess the utility of a combination of antibody and fusion inhibitor treatments, we investigated the potency of monoclonal antibodies at neutralizing HIV-1 variants that are resistant to fusion inhibitors. …

    Retrovirology 13(1), 2016-09-27

    IR 

  • The Dramatic and Long-lasting Effect of Alectinib Against Crizotinib-resistant Leptomeningeal Carcinomatosis in a Patient with ALK-positive Lung Cancer  [in Japanese]

    Katsurada Masahiro , Misawa Masafumi , Suzuki Fumi , Katsurada Naoko , Aoshima Masahiro

    <p><b>背景.</b>ALK融合遺伝子陽性非小細胞癌に対しALK阻害薬は有効な薬剤であるが,多くは耐性化する.また癌性髄膜症は治療抵抗性であり致死的転帰を辿る重篤な病態である.今回我々は,クリゾチニブ耐性髄膜症にアレクチニブが劇的に奏効し,その後も持続奏効した1例を経験したため報告する.<b>症例.</b>45歳女性.ALK融合遺伝子 …

    Haigan 56(4), 263-267, 2016

    J-STAGE  Ichushi Web 

  • Circumvention of Resistance to Tyrosine kinase Inhibitors : HDAC and HSP90  [in Japanese]

    竹内 伸司

    日本胸部臨床 74(6), 627-637, 2015-06

    Ichushi Web 

  • Past and Current Developments in ALK-TKI Resistant NSCLC  [in Japanese]

    Hattori Yoshihiro

    2007年にALK融合遺伝子陽性肺癌が報告され,2010年にはALKチロシンキナーゼ阻害剤(TKI)であるCrizotinib(ザーコリ<sup>®</sup>)の有効性が報告されたことより,2012年には本邦においても日常臨床に導入されるようになった.また,2014年にはAlectinib(アレセンサ<sup>®</sup>)が世界に先駆けて臨床導 …

    Haigan 55(6), 936-940, 2015

    J-STAGE  Ichushi Web 

  • Treatment of acute myeloid leukemia carrying inv(2)(p23q13)/<i>RANBP2-ALK</i><i> </i>with crizotinib and the mechanism of resistance to the drug  [in Japanese]

    Takeoka Kayo , Okumura Atsuko , Kishimori Chiyuki , Honjo Gen , Izumi Kiyotaka , Maesako Yoshitomo , Akasaka Takashi , Ohno Hitoshi

    fusion mRNAを検出し,PCR産物のシークエンシングで<i>RANBP2</i> …

    Tenri Medical Bulletin 18(2), 80-85, 2015

    J-STAGE  Ichushi Web 

  • SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1

    Minami Yusuke , Kohsaka Shinji , Tsuda Masumi , Yachi Kazuhiro , Hatori Nobuaki , Tanino Mishie , Kimura Taichi , Nishihara Hiroshi , Minami Akio , Iwasaki Norimasa , Tanaka Shinya

    Cancer Science 105(9), 1152-1159, 2014-09

    IR  Ichushi Web 

  • Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group

    Itonaga Hidehiro , Tsushima Hideki , Imanishi Daisuke , Hata Tomoko , Doi Yuko , Mori Sayaka , Sasaki Daisuke , Hasegawa Hiroo , Matsuo Emi , Nakashima Jun , Kato Takeharu , Horai Makiko , Taguchi Masataka , Matsuo Masatoshi , Taniguchi Hiroaki , Makiyama Junnya , Sato Shinya , Horio Kensuke , Ando Koji , Moriwaki Yuji , Sawayama Yasushi , Ogawa Daisuke , Yamasaki Reishi , Takasaki Yumi , Imaizumi Yoshitaka , Taguchi Jun , Kawaguchi Yasuhisa , Yoshida Shinichiro , Joh Tatsuro , Moriuchi Yukiyoshi , Nonaka Hiroaki , Soda Hisashi , Fukushima Takuya , Nagai Kazuhiro , Kamihira Shimeru , Tomonaga Masao , Yanagihara Katsunori , Miyazaki Yasushi

    … We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. … Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. …

    Leukemia Research 38(1), 76-83, 2014-01

    IR 

  • Synip phosphorylation is required for insulin-stimulated Glut4 translocation and glucose uptake in podocyte [Rapid Communication]

    Yamada Eijiro , Yamada Masanobu , Saito Tsugumichi , Okada Shuichi , Takahashi Hiroki , Ohshima Kihachi , Hashimoto Koshi , Satoh Tetsurou , Mori Masatomo , Okada Junichi

    … Recently Synip was reported to arrest SNARE-dependent membrane fusion as a selective t-SNARE binding inhibitor. … We conclude that serine 99 phosphorylation of Synip is required for Glut4 translocation and glucose uptake in both adipocytes and podocytes, suggesting that defects in Synip phosphorylation may underlie insulin resistance and associated diabetic nephropathy. …

    Endocrine Journal 61(5), 523-527, 2014

    J-STAGE  Ichushi Web 

  • Resistant mechanism to ALK inhibitors  [in Japanese]

    清家 正博 , 久保田 馨

    腫瘍内科 10(6), 558-562, 2012-12

    Ichushi Web 

  • Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands

    Yano Seiji , Takeuchi Shinji , Nakagawa Takayuki , Yamada Tadaaki

    … がん進展制御研究所Recent advances in molecular biology have led to the identification of new molecular targets, such as epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) fusion gene, in lung cancer. … Dramatic response has been achieved with EGFR inhibitors (gefitinib and erlotinib) and an ALK inhibitor (crizotinib) in lung cancer expressing corresponding targets. …

    Cancer Science 103(7), 1189-1194, 2012-07-01

    IR  Ichushi Web 

  • Bioorganic synthesis of a recombinant HIV-1 fusion inhibitor, SC35EK, with an N-terminal pyroglutamate capping group.

    Kajiwara Kazumi , Watanabe Kentaro , Tokiwa Rei , Kurose Tomoko , Ohno Hiroaki , Tsutsumi Hiroko , Hata Yoji , Izumi Kazuki , Kodama Eiichi , Matsuoka Masao , Oishi Shinya , Fujii Nobutaka

    … Cyanogen bromide-mediated cleavage of two Met-Gln sites across the target anti-HIV sequence generated an HIV-1 fusion inhibitor (SC35EK) analog bearing an N-terminal pyroglutamate (pGlu) residue and a C-terminal homoserine lactone (Hsl) residue. …

    Bioorganic & medicinal chemistry 17(23), 7964-7970, 2009-12-01

    IR 

  • X-ray Crystallographic Study of the HIV-1 Fusion Inhibitor against the Drug-Resistant N43D Variant

    WATABE Tsuyoshi , OISHI Shinya , WATANABE Kentaro , OHNO Hiroaki , NAKANO Hiroaki , NAKATSU Toru , KATO Hiroaki , IZUMI Kazuki , KODAMA Eiichi , MATSUOKA Masao , FUJII Nobutaka

    Peptide science : proceedings of the ... Japanese Peptide Symposium 2008, 229-232, 2009-03-01

    References (11)

  • Identification of minimal sequence for HIV-1 fusion inhibitors.

    Nishikawa Hiroki , Oishi Shinya , Fujita Mizuno , Watanabe Kentaro , Tokiwa Rei , Ohno Hiroaki , Kodama Eiichi , Izumi Kazuki , Kajiwara Keiko , Naitoh Takeshi , Matsuoka Masao , Otaka Akira , Fujii Nobutaka

    … Recently, the virus-cell membrane fusion process has been identified as a promising target for the development of novel drugs against these resistant variants. … In this study, we identified a 29-residue peptide fusion inhibitor, SC29EK, which shows activity comparable to the previously reported inhibitor SC35EK. …

    Bioorganic & medicinal chemistry 16(20), 9184-9187, 2008-10-15

    IR  Cited by (1)

  • Analysis of Brassinosteroid Signaling Mutant <I>bil</I>(<I>brz-insensitive-long hypocotyl</I>)

    Nakano Takeshi , Yoshida Shigeo , Chory Joanne , Asami Tadao , Wang Zhiyong , Mora-Garcia Santiago , Kanda Satomi , Suzuki Takeyuki , Nagata Noriko , Sakuta Masaaki , 内藤 忠雄 , Fujioka Shozo

    ブラシノステロイド生合成阻害剤Brz培地上で暗所発芽した植物体は、暗所ながら光形態形成や葉緑体遺伝子の発現が認められる。この暗所Brz条件下におけるBrz耐性を指標にアラビドプシス突然変異体bilのスクリーニングを行っている。現時点で最も形質の強い<I>bil1</I>はDominant変異であり、<I>bzr1<I>(<I>Brz-re …

    Plant and Cell Physiology Supplement 2003(0), 183-183, 2003

    J-STAGE 

  • Identification of Amino Acids of Influenza Virus HA Responsible for Resistance to a Fusion Inhibitor, Stachyflin

    YOSHIMOTO Jun , KAKUI Mayumi , IWASAKI Hiroko , SUGIMOTO Hirohiko , FUJIWARA Tamio , HATTORI Naohiko

    … We have recently described a novel hemagglutinin (HA) conformational change inhibitor of human influenza virus, Stachyflin (Yoshimoto et al, Arch. … The relation of amino acid substitutions and Stachyflin resistance was analyzed with <i>in vitro</i> … membrane fusion between HA-expressing cells and octadecylrhodamine (R18)-labelled chick erythrocytes (RBC). …

    MICROBIOLOGY and IMMUNOLOGY 44(8), 677-685, 2000-08-20

    J-STAGE  Ichushi Web  References (27) Cited by (1)

  • Identification of Amino Acids of Influenza Virus HA Responsible for Resistance to a Fusion Inhibitor, Stachyflin

    Yoshimoto Jun , Kakui Mayumi , Iwasaki Hiroko , Sugimoto Hirohiko , Fujiwara Tamio , Hattori Naohiko

    … We have recently described a novel hemagglutinin (HA) conformational change inhibitor of human influenza virus, Stachyflin (Yoshimoto et al, Arch. … The relation of amino acid substitutions and Stachyflin resistance was analyzed with <i>in vitro</i> … membrane fusion between HA-expressing cells and octadecylrhodamine (R18)-labelled chick erythrocytes (RBC). …

    Japanese Journal of Microbiology 44(8), 677-685, 2000

    J-STAGE 

Page Top